Study of the histone deacetylase inhibitor Panobinostat (LBH589) in combination with standard dose Cytarabine and Daunorubicin for older patients with untreated acute Mmyeloid leukemia or advanced myelodysplasia

Investigator: Charalambos (Babis) Andreadis, MD
Sponsor: Novartis Pharma AG

Location(s): United States


The purpose of this study is to see if Panobinostat is safe to give to patients and to determine the best dose to give in combination with standard cytarabine and daunorubicin chemotherapy.